Toyota has announced a recall of recent model year vehicles to repair accelerator pedals in many of their car models. The pedals may stick in cars without floor mats.

The best bad credit credit cards are those that actually help a cardholder to rebuild their credit without excessive fees and charges.

Buying a car used can be made simpler by using three online tools that give car buyers indispensable knowledge when negotiating a car deal.

The commercial printing industry is ripe for M&A. First of all, the market is highly fragmented, with 30,000 printers in the United States. About 400 companies control less than 30% of the market. Next, the printing industry has been undergoing significant change, as print media has declined because of the rise of the Internet. Finally, the global recession has been brutal and there is much overcapacity in the industry.

Continue reading Quad/Graphics-World Color Deal Signals M&A Hits Commercial Printers

Quad/Graphics-World Color Deal Signals M&A Hits Commercial Printers originally appeared on DailyFinance on Tue, 26 Jan 2010 19:45:00.

Filed Under: Economy

Toyota said Tuesday it was suspending U.S. sales of eight recalled vehicle models to fix accelerator pedals that stick, the latest quality problem to confront the world's No. 1 automaker.

Continue reading Toyota Halts U.S. Sales of 8 Recalled Vehicle Models

Toyota Halts U.S. Sales of 8 Recalled Vehicle Models originally appeared on DailyFinance on Tue, 26 Jan 2010 19:01:00.

Filed Under: Toyota

Time was, telecommunications giant AT&T (T) was one of the most important earnings reports of the season. While times have changed, investors can still get a pretty good sense of where the U.S. economy is headed from AT&T's quarterly report, slated for Thursday ahead of the opening bell.

Continue reading Earnings Preview: AT&T to Ring Up Higher Profit

Earnings Preview: AT&T to Ring Up Higher Profit originally appeared on DailyFinance on Tue, 26 Jan 2010 18:55:00.

Filed Under: Company News, Earnings, AT&T

The U.S. Food and Drug Administration has finally approved Novo Nordisk's (NVO) new once-daily injection for treating Type 2 diabetes, Victoza. Shares on Tuesday jumped about 3.8% in early afternoon trading in response to Monday's approval, as it came after some delays due to safety concerns. The Danish drug maker plans to launch Victoza in the U.S. within weeks.

Continue reading Diabetes Drug Approval Lifts Novo Nordisk, Amylin Stock

Diabetes Drug Approval Lifts Novo Nordisk, Amylin Stock originally appeared on DailyFinance on Tue, 26 Jan 2010 17:45:00.

Filed Under: Company News, Healthcare, Eli Lilly

EBay (EBAY), the giant online auctioneer, said Tuesday it is eliminating "listing" fees for occasional sellers, as it tries to entice more users to its website in the face of stiff competition from arch rival Amazon (AMZN). Starting Mar. 30, sellers they will be able to list up to 100 items every month for free; eBay will take 9% of the final sale price, or $50, whichever is less. The company also said it would reduce listing fees for fixed price "Buy-It-Now" goods.

Continue reading EBay Rolls Out 'Free' Auction Listings to Attract More Sellers

EBay Rolls Out 'Free' Auction Listings to Attract More Sellers originally appeared on DailyFinance on Tue, 26 Jan 2010 17:25:00.

Filed Under: Amazon.com Inc., eBay

Yahoo (YHOO) CEO Carol Bartz may have stanched the bleeding, but she hasn't yet cured the patient. That was the bottom line Tuesday as the beleaguered Web giant posted lackluster results, meeting Wall Street expectations. After hours, the company's strong guidance sent the company's shares higher. For the current quarter, Yahoo forecast revenue between $1.6 billion and $1.7 billion, significantly higher than the $1.2 billion analysts had been expecting.

Continue reading Yahoo Stops the Bleeding, but So-So Results Signal Long Road Ahead

Yahoo Stops the Bleeding, but So-So Results Signal Long Road Ahead originally appeared on DailyFinance on Tue, 26 Jan 2010 17:00:00.

Filed Under: Earnings, Google , Yahoo

Novartis (NVS) reported a remarkable 54% increase in fourth-quarter net income to $2.3 billion, just slightly below analysts' expectations of $2.4 billion. The Swiss drugmaker's net sales also shot up 28% to $12.9 billion, helped by its H1N1 swine flu vaccines. Novartis also announced its new chief executive and a slimmed-down board. Joe Jimenez (left), currently division head of the pharmaceutical business, will replace Daniel Vasella (right) as the company's new CEO. Vasella, who has led the company since it was formed in 1996 through the merger of Ciba-Geigy and Sandoz Labs, will remain chairman.

Continue reading Novartis Investors Cheer Strong Earnings and New CEO

Novartis Investors Cheer Strong Earnings and New CEO originally appeared on DailyFinance on Tue, 26 Jan 2010 16:29:00.

Filed Under: Company News, Healthcare, Earnings, Novartis